Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,672 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. Goldberg SB, et al. Among authors: moon j. J Clin Oncol. 2020 Dec 1;38(34):4076-4085. doi: 10.1200/JCO.20.01149. Epub 2020 Oct 6. J Clin Oncol. 2020. PMID: 33021871 Free PMC article. Clinical Trial.
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. Samlowski WE, et al. Among authors: moon j. Cancer Invest. 2007 Apr-May;25(3):182-8. doi: 10.1080/07357900701209061. Cancer Invest. 2007. PMID: 17530488 Clinical Trial.
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Hesketh PJ, et al. Among authors: moon j. J Thorac Oncol. 2008 Sep;3(9):1026-31. doi: 10.1097/JTO.0b013e318183aa1f. J Thorac Oncol. 2008. PMID: 18758306 Free PMC article. Clinical Trial.
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC. Gandara DR, et al. Among authors: moon j. J Clin Oncol. 2009 Jul 20;27(21):3540-6. doi: 10.1200/JCO.2008.20.8793. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470925 Free PMC article.
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS. Markman M, et al. Among authors: moon j. Gynecol Oncol. 2010 Mar;116(3):323-5. doi: 10.1016/j.ygyno.2009.11.026. Epub 2009 Dec 30. Gynecol Oncol. 2010. PMID: 20044128 Free PMC article. Clinical Trial.
Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study.
Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS. Tiersten AD, et al. Among authors: moon j. Oncology. 2009;77(6):395-9. doi: 10.1159/000279386. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130422 Free PMC article.
7,672 results